Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis

BMC Cancer

Research Article

Pengfei Pang¹  Rongfeng Song²  Rong Cai³  Yan Yan³  Huaping Wang³  Yifeng Liao³  Haiqing Ma³  Cuiling Zhou³  Hongyu Zhang³  Shuncong Wang³  Xiuling Zhou³  Huanhuan Sun³ 

[1] Center for Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China;Guangdong Provincial Engineering Research Center for Molecular Imaging, 519000, Zhuhai, Guangdong, China;Institute of Interventional Radiology, Sun Yat-sen University, 519000, Zhuhai, Guangdong, China;Department of Gastroenterology, Cancer Hospital of Jiangxi Province, 330029, Nanchang, Jiangxi, China;Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China;

关键词: Transcatheter arterial chemoembolization;    TACE;    Advanced hepatocellular carcinoma;    Sorafenib;    Clinical trial;   

DOI  :  10.1186/s12885-017-3707-5

 received in 2017-03-16, accepted in 2017-10-27,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundMany studies have combined sorafenib with transcatheter arterial chemoembolization (TACE) to treat patients with advanced hepatocellular carcinoma (HCC), but the results are disputable. Thus, we conducted this meta-analysis to assess the efficacy and safety of the combination treatment in patients with advanced HCC.MethodsClinical data were collected from a computer search of literature published from January 2009 to June 2016 in PubMed, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang and the China Science and Technology Journal Database (CSTJ). The final analysis included 14 studies and 1670 patients. The primary endpoints were overall survival (OS), the objective response rate (ORR) and the disease control rate (DCR).ResultsThe combination group exhibited significantly more improvement than the group treated with TACE alone in ORR (RR =1.62, 95% confidence interval (CI) = 1.34–1.94, p < 0.00001), DCR (RR = 1.43, 95% CI = 1.26–1.62, p < 0.00001), 0.5-year OS (OR = 2.60, 95% CI = 1.57–4.29, p = 0.0002) and 1-year OS (OR = 1.88, 95% CI =1.39–2.53, p < 0.0001). The incidence of adverse events from combination therapy was increased compared to that from treatment with TACE alone, and the most commonly reported adverse events were fatigue, hand-foot skin reaction and diarrhoea, which were bearable.ConclusionsThe meta-analysis indicated that combination therapy is safe and efficient for clinical application.

【 授权许可】

CC BY   
© The Author(s). 2017